|
|
|
| Prognosis and Tumor Marker Changes of Concurrent Chemoradiotherapy Combined with DC-CIK Cell Immunotherapy in NSCLC |
| YUAN Ying-xuan, LI Qiao-tao, YUAN Lin |
| Department of Laboratory Medicine,Xi'an Electric Power Central Hospital,Xi'an Shaanxi 710032 |
|
|
|
|
Abstract 【Objective】To investigate the effect of concurrent chemoradiotherapy combined with dendritic cell-cytokine-induced natural killer (DC-CIK) cell immunotherapy on the prognosis and tumor marker levels of non-small cell lung cancer (NSCLC). 【Methods】Seventy-two NSCLC patients were randomly divided into the control group and the observation group,with 36 cases in each group. The control group was treated with TP regimen (paclitaxel + cisplatin) combined with intensity-modulated radiotherapy (IMRT),while the observation group was treated with DC-CIK cellular immunotherapy on the basis of treatment in the control group. The curative effect,peripheral blood T lymphocyte subsets (CD3+,CD4+,CD8+,CD4+/CD8+),serum microRNA-137 (miR-137),microRNA-29a (miR-29a) and serum tumor markers were compared between the two groups before and after treatment. Changes in the levels of substances [carbohydrate antigen 125 (CA-125),carcinoembryonic antigen (CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)] were compared as well. The incidence of adverse reactions in the two groups was observed. 【Results】The objective remission rate (RR) of the observation group was 94.44% (34/36),which was higher than that of the control group of 77.78% (28/36) (P<0.05). After treatment,CD3+,CD4+,CD4+/CD8+ in the two groups were higher than those before treatment (P<0.05),and CD8+ was lower than those before treatment (P<0.05). And after treatment,CD3+,CD4+,CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05),there was no significant difference in CD8+ compared with the control group (P>0.05). After treatment,the levels of miR-137,miR-29a,CA-125,CEA,and CYFRA21-1 in the two groups were lower than those before treatment (P<0.05); and the levels of each index in the observation group were lower than those in the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Concurrent chemoradiotherapy combined with DC-CIK cellular immunotherapy can improve the curative effect of NSCLC patients,down-regulate the expression of miR-137 and miR-29a,improve the immune function and serum tumor markers of patients. And the risk of adverse reactions is low,which is worthy of clinical promotion.
|
|
Received: 15 March 2022
|
|
|
|
|
|
[1] POWELL S F,D RODRrIGUEZ-ABREU,LANGER C J,et al. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with non-small-cell lung cancer and stable brain metastases:pooled analysis of KEYNOTE-021,189,and 407[J].J Thorac Oncol,2021,16(11):1883-1892.
[2] 孙祝,赵玉魁,孙宇,等. 调强放疗联合化疗治疗非小细胞肺癌的疗效观察及肿瘤标志物的变化意义[J].川北医学院学报,2020,35(4):713-716.
[3] 李洪水,廖丽娟. IMRT放疗对中晚期非小细胞肺癌患者肺功能及血清肿瘤标志物的影响[J].实用癌症杂志,2018,33(7):1145-1147.
[4] 陆婉玲,李小龙,党亚正,等. DC-CIK免疫疗法联合放化疗治疗中晚期非小细胞肺癌疗效观察[J].疑难病杂志,2020,19(8):804-807.
[5] 覃帮能,刘触灵. CT诊断非小细胞肺癌TNM分期的临床价值[J].重庆医学,2017,46(31):4406-4408.
[6] WOOD D E,KAZEROONI E A,BAUM S L,et al. Lung cancer screening,version 3.2018,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2018,16(4):412-441.
[7] 孙明华. DC-CIK细胞免疫治疗联合化疗对老年中晚期非小细胞肺癌的临床研究[J].国际老年医学杂志,2019,40(6):324-327.
[8] 杨学宁,吴一龙.实体瘤治疗疗效评价标准:RECIST[J].循证医学,2004,4(2):85-90.
[9] LI B,ZHU L,LU C,et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity[J].Nat Commun,2021,12(1):295.
[10] 蔡龙玉. 调强放疗与立体定向体部放疗同步化疗对Ⅲ期非小细胞肺癌患者免疫功能及血清细胞因子的影响[J].贵州医药,2021,45(3):367-368.
[11] 李工,孔怡琳,詹文婷,等. 三维适形／调强放疗结合化疗联合 DC-CIK 免疫治疗Ⅱ,Ⅲ期非小细胞肺癌疗效分析[J].安徽医药,2015,19(7):1358-1360.
[12] 崔凯,支亚男,王壮壮,等. 微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214-1222. |
|
|
|
2022, Vol. 39 
